Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Receives $25.60 Consensus Target Price from Analysts

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) has received a consensus rating of “Buy” from the six brokerages that are covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have covered the stock in the last year is $25.60.

A number of equities analysts have issued reports on ATNM shares. Stephens started coverage on shares of Actinium Pharmaceuticals in a report on Tuesday, May 14th. They issued an “overweight” rating and a $25.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $21.00 target price on shares of Actinium Pharmaceuticals in a report on Tuesday, April 30th. StockNews.com raised shares of Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, May 5th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Actinium Pharmaceuticals in a report on Monday, June 17th. Finally, Maxim Group lifted their price target on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, March 19th.

Actinium Pharmaceuticals Trading Up 0.9 %

Shares of NYSEAMERICAN ATNM opened at $7.45 on Wednesday. Actinium Pharmaceuticals has a 52-week low of $4.00 and a 52-week high of $10.24. The stock has a market capitalization of $221.86 million, a price-to-earnings ratio of -4.36 and a beta of 0.20.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last issued its earnings results on Friday, April 26th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.11. As a group, analysts anticipate that Actinium Pharmaceuticals will post -1.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Creative Financial Designs Inc. ADV increased its stake in shares of Actinium Pharmaceuticals by 19.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock valued at $101,000 after acquiring an additional 3,175 shares during the period. Sanders Morris Harris LLC acquired a new position in Actinium Pharmaceuticals in the first quarter worth approximately $78,000. Virtu Financial LLC grew its position in Actinium Pharmaceuticals by 319.2% in the first quarter. Virtu Financial LLC now owns 82,029 shares of the biotechnology company’s stock worth $642,000 after buying an additional 62,459 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in Actinium Pharmaceuticals by 6.0% in the first quarter. Vanguard Group Inc. now owns 1,446,326 shares of the biotechnology company’s stock worth $11,325,000 after buying an additional 82,113 shares during the last quarter. Institutional investors and hedge funds own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.